Welcome to the e-CCO Library!

P460: A Real-World Picture of Adverse Drug Reactions in Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Lemos Garcia, J.(1);Rosa, I.(2);Saraiva, S.(2);Moleiro, J.(2);Claro, I.(2);
Created: Friday, 11 February 2022, 3:52 PM
P460: Biomarkers reflecting extracellular matrix turnover and inflammation can be used to monitor disease activity and treatment response in patients with Crohn’s disease undergoing infliximab induction therapy
Year: 2021
Source: ECCO'21 Virtual
Authors: Sorokina Alexdóttir, M.(1);Bourgonje, A.R.(2);Asser Karsdal, M.(1);Bay-Jensen, A.C.(1);Faber, K.N.(2);Loveikyte, R.(2);van Dullemen, H.M.(2);Visschedijk, M.C.(2);Festen, E.A.M.(2);Weersma, R.K.(2);Dijkstra, G.(2);Mortensen, J.H.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P460: Early use of therapeutic drug monitoring to individualize infliximab therapy in paediatric IBD: a multicentre prospective COHORT study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Crowley E.*1, Carman N.1, Arpino V.1, Frost K.1, Ricciuto A.1, Sherlock M.2, Critch J.3, Mack D.4, Benchimol E.5, Jacobson K.6, Lawrence S.6, deBruyn J.7, El-Matary W.8, Otley A.9, Huynh H.10, Church P.1, Walters T.1, Griffiths A.1

Created: Wednesday, 20 February 2019, 10:36 AM
P460: Effect of fertility treatment on inflammatory bowel disease outcomes
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Bejaoui*, C. Landman, J. Kirchgesner, A. Bourrier, I. Nion-Larmurier, H. Sokol, L. Beaugerie, J. Cosnes, P. Seksik

Created: Friday, 22 February 2019, 9:49 AM
P460: Efficacy of ustekinumab in patients with anti-TNF refractory Crohn’s disease: data from a real-world study in Brazil
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. S. Parra*1, M. R. Feitosa1, O. Féres1, J. J. Ribeiro da Rocha1, J. M. F. Chebli2, L. Chebli2, E. R. Bertges2, T. N. F. Gomes3, O. Ambrogini Jr3, A. J. T. Alves Junior4, M. Lubini5

Created: Friday, 22 February 2019, 9:41 AM
P460: Impact of anti-TNFα exposure during pregnancy for maternal inflammatory bowel disease on serologic response to vaccination of exposed children
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Duricová1*, E. Dvorakova1, J. Kozeluhova2, P. Kohout3, K. Mitrova4, M. Durilova5, K. Zarubova4, O. Hradsky4, J. Bronsky4, N. Hradska6, E. Bronska6, N. Machkova1, V. Hruba1, M. Bortlik1, M. Lukas1, K. Malickova1, M. Lukas1

Created: Thursday, 21 February 2019, 9:14 AM
P460: Preoperative nutrition supplementation may prevent one-year endoscopic recurrence in Crohn's disease patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Inniss, S.(1,2)*;Simpson, K.(1);Fragkos, K.(1);Wood, C.(1);Smith, A.(2);Rahman, F.(1,2);
Created: Friday, 14 July 2023, 11:05 AM
P461 Intolerance to 5-aminosalicylate is a risk of poor prognosis in ulcerative colitis patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Fujii1, S. Hibiya1, C. Maeyashiki2, E. Saito1, K. Takenaka1, M. Motobayashi1, H. Shimizu1, M. Nagahori1, K. Ohtsuka1, M. Kurosaki2, T. Yauchi3, M. Watanabe1

Created: Thursday, 30 January 2020, 10:12 AM
P461: Clinical benefit of adalimumab after surgery in the treatment of complex perianal Crohn’s disease: a tertiary referral centre experience
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. Solina*1, S. Renna2, E. Orlando2, M. Affronti2, M. Cottone2, A. Orlando2

Created: Friday, 22 February 2019, 9:49 AM
P461: Comparison of efficacy of different oral 5-aminosalicylic acid doses for maintenance of remission in ulcerative colitis: a systematic review and meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Choi C.H.*1, Kim Y.S.2, Moon W.3, Lee B.I.4, Kim E.S.5, Jung Y.6, Park D.I.7, Yoon Y.S.8, Lee H.9, Han D.S.10

Created: Wednesday, 20 February 2019, 10:36 AM
P461: COVID-19 outcomes in patients receiving anti-TNF treatments: A systematic review and meta-analysis
Year: 2022
Source: ECCO'22
Authors: Kokkotis, G.(1);Kitsou, K.(2);Xynogalas, I.(3);Spoulou, V.(2);Magiorkinis, G.(4);Poulakou, G.(3);Syrigos, K.(3);Bamias, G.(1);
Created: Friday, 11 February 2022, 3:52 PM
P461: Endoscopic features for loss of response in patients with Crohn’s disease who were treated with infliximab by top-down strategy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Miyazaki*1, K. Watanabe2, K. Kojima1, R. Koshiba1, K. Fujimoto1, T. Sato2, M. Kawai1, K. Kamikozuru1, T. Takagawa1, Y. Yokoyama2, N. Hida1, S. Nakamura1

Created: Friday, 22 February 2019, 9:41 AM
P461: Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Travis1, R. Ungaro2, A. Blake3, F. Bhayat4*, T. Card5

Created: Thursday, 21 February 2019, 9:14 AM
P461: Rapid response to appendectomy in the majority of patients with refractory Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Adamou, A.(1)*;Bercher, M.(1);Iesalnieks, I.(1);Streetz, K.(2);
Created: Friday, 14 July 2023, 11:05 AM
P461: Vedolizumab Dose Escalation in a Real-World Cohort of IBD Patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Zelinkova, Z.(1);Kadleckova, B.(1);Lucenicova, J.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P462 Efficacy of ustekinumab for the prevention of postoperative recurrence in crohn’s disease. Data from clinical practice from the eneida registry
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Mañosa Ciria1, A. Fernandez-Clotet2, A. Hernández-Camba3, R. Muñoz Pérez4, M. Iborra5, M. Sierra6, L. Márquez7, P. Delgado-Guillena8, D. Busquets9, M. Van Domselaar10, E. Girona11, E. Sánchez-Rodríguez12, M.D. Martín-Arranz13, R. Lorente14, D. Casas-Deza15, M. Boscá16, F. Cañete1, M. Calafat1, E. Domènech1

Created: Thursday, 30 January 2020, 10:12 AM
P462: Adalimumab improves treatment satisfaction with medication and work productivity amongst patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Travis*1, B. Feagan2, L. Peyrin-Biroulet3, R. Panaccione4, S. Danese5, A. Lazar6, A. Robinson7, J. Petersson7, M. Bereswill6, M. Skup7, N. Chen7, S. Wang7, R. Thakkar7, J. Chao7

Created: Friday, 22 February 2019, 9:49 AM
P462: Delayed Responders with Ustekinumab in Ulcerative Colitis Have Increased Inflammatory Burden but Similar Long-term Outcomes as Early Responders
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Wong, E.(1);Dulai, P.(2);Marshall, J.(1);Jairath, V.(3);Reinisch, W.(4);Narula, N.(1)*;
Created: Friday, 14 July 2023, 11:05 AM
P462: Dietary restrictions on inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Macedo*1, F. Portela1, A. M. Ferreira1, S. Lopes1, S. Mendes1, M. Ferreira1, L. Tomé1

Created: Friday, 22 February 2019, 9:41 AM
P462: Impact of teduglutide, a GLP-2 agonist, on inflammatory bowel disease-associated short bowel syndrome: a tertiary single-center study
Year: 2021
Source: ECCO'21 Virtual
Authors: de Seze, M.(1);Billiauws, L.(1);Bettolo, J.(1);Damas, V.(1);Hutinet, C.(1);Bonvalet, F.(2);Cazals-Hatem, D.(3);Villain, C.(1);Bouhnik, Y.(1);Joly, F.(1);Uzzan, M.(4);
Created: Wednesday, 2 June 2021, 4:12 PM